COF 004
Alternative Names: COF-004Latest Information Update: 23 Sep 2022
Price :
$50 *
At a glance
- Originator China Cancer Medical
- Developer China Cancer Medical; Lee's Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Cancer
Most Recent Events
- 23 Sep 2022 COF 004 is still in preregistration for Cancer in China (unspecified route) (Lee's Pharma pipeline, September 2022)
- 17 Jul 2020 Preregistration for Cancer in China (unspecified route) (Lee's Pharma pipeline, prior to July 2020)
- 17 Jul 2020 China Cancer Medical submits application to regulatory authority for Cancer (Lee's Pharma pipeline, prior to July 2020)